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Previewsdoes not increase b cell regeneration in
humans (Menge et al., 2008), and our
group recently showed that whatever the
stimulus for b cell replication in mice
treated with S961, it had no effect on
transplanted human b cells (Jiao et al.,
2014). Perhaps human b cells are less
responsive to the insulin-resistant state
and need additional ‘‘prodding’’ to re-
enter the cell cycle, such as, for instance,
through suppression of cell-cycle inhibi-
tors (Avrahami et al., 2014). What is clear
from the betatrophin saga is that the prob-
lem of increasing b cell replication and
mass is complicated. Referees and edi-
tors must weigh the excitement of a new
finding versus the level of proof required
to make it public. While the scientific en-
terprise is benefitted by enthusiasm in
the lay public, we must also weigh thenegative consequences of not being
able to keep promises of widely publi-
cized discoveries.REFERENCES
Avrahami, D., Li, C., Yu, M., Jiao, Y., Zhang, J.,
Naji, A., Ziaie, S., Glaser, B., and Kaestner, K.H.
(2014). J. Clin. Invest. 124, 670–674.
Flier, S.N., Kulkarni, R.N., and Kahn, C.R. (2001).
Proc. Natl. Acad. Sci. USA 98, 7475–7480.
Gusarova, V., Alexa, C.A., Na, E., Stevis, P.E., Xin,
Y., Bonner-Weir, S., Cohen, J.C., Hobbs, H.H.,
Murphy, A.J., Yancopoulos, G.D., and Gromada,
J. (2014). Cell 159, 691–696.
Jiao, Y., Le Lay, J., Yu, M., Naji, A., and Kaestner,
K.H. (2014). Diabetes 63, 1283–1288.
Menge, B.A., Tannapfel, A., Belyaev, O., Drescher,
R., Mu¨ller, C., Uhl, W., Schmidt, W.E., and Meier,
J.J. (2008). Diabetes 57, 142–149.Cell Metabolism 20,Michael, M.D., Kulkarni, R.N., Postic, C., Previs,
S.F., Shulman, G.I., Magnuson, M.A., and Kahn,
C.R. (2000). Mol. Cell 6, 87–97.
Scha¨ffer, L., Brand, C.L., Hansen, B.F., Ribel,
U., Shaw, A.C., Slaaby, R., and Sturis, J.
(2008). Biochem. Biophys. Res. Commun. 376,
380–383.
Wang, Y., Quagliarini, F., Gusarova, V., Gromada,
J., Valenzuela, D.M., Cohen, J.C., and Hobbs,
H.H. (2013). Proc. Natl. Acad. Sci. USA 110,
16109–16114.
Withers, D.J., Gutierrez, J.S., Towery, H., Burks,
D.J., Ren, J.M., Previs, S., Zhang, Y., Bernal, D.,
Pons, S., Shulman, G.I., et al. (1998). Nature 391,
900–904.
Yi, P., Park, J.-S., and Melton, D.A. (2013). Cell
153, 747–758.
Yi, P., Park, J.-S., and Melton, D.A. (2014). Cell
159, 467–468.Expanding the Brain Glucosensing TerritoryIvan E. de Araujo1,2,3,*
1The J.B. Pierce Laboratory, 290 Congress Ave, New Haven, CT 06519, USA
2Department of Psychiatry, Yale University School of Medicine, 300 George Street, Suite 901, New Haven, CT 06511, USA
3Department of Physiology, Yale University School of Arts and Sciences, 320 York Street, New Haven, CT 06511, USA
*Correspondence: iaraujo@jbpierce.org
http://dx.doi.org/10.1016/j.cmet.2014.11.013
Brain glucosensing neurons monitor extracellular glucose concentrations and act to defend normoglycemia.
To date, the majority of these neurons have been ascribed to hypothalamic and hindbrain centers. In this
issue, Garfield and colleagues (2014) demonstrate that cholecystokinin-expressing neurons in the rodent
parabrachial nucleus function as glucosensors that counter-regulate hypoglycemia.The parabrachial nucleus (PBN) is a
dorsolateral pontine structure located
around the superior cerebellar peduncle
comprising a diverse population of genet-
ically defined neurons. PBN contains two
main subdivisions, named according
to where they stand in relation to the
peduncle: the medial and lateral PBN
(LPBN). LPBN has been associated with
appetite suppression, as it mediates the
anorectic actions of a number of gut hor-
mones (Becskei et al., 2007). Recently,
the LPBN has been more specifically
linked to a ‘‘permissive’’ role in food
intake. In fact, a distinct subpopulation
of LPBN cells located in its outer external
subdivision, namely the calcitonin gene-related peptide-expressing (CGRPLPBN)
neurons, have been described as medi-
ating appetite suppression in conditions
when it is unfavorable to eat (such as dur-
ing bacterial infections or visceral malaise
[Carter et al., 2013]).
Notwithstanding its critical role in food
intake, the glucosensing and counter-
regulatory functions of LPBN remained
largely unsuspected. In this issue, Gar-
field and colleagues (2014) show that a
distinct subpopulation of LPBN neurons
expressing the peptide cholecystokinin
(CCKLPBN) constitutes an unanticipated
group of glucosensing counter-regulatory
cells. Garfield et al. (2014) first demon-
strated using whole-cell recordings thatdownward shifts in extracellular glucose
resulted in reversible membrane depolar-
ization in approximately 50% of CCKLPBN
neurons tested. The authors then aimed
at observing the effects of silencing
CCKLPBN neurons in vivo. Using Cre-
dependent viral expression of DREADDs
(designer receptors exclusively activated
by designer drugs), Garfield et al. (2014)
selectively suppressed the activity of
CCKLPBN neurons in a cell-specific
manner. They observed that CCKLPBN
neuronal silencing upon administering
the designer drug impaired counter-
regulatory responses to glucoprivation
in vivo. Conversely, DREADD-mediated
excitation of CCKLPBN neurons inducedDecember 2, 2014 ª2014 Elsevier Inc. 933
Figure 1. TheGenetic Diversity of LPBNMay
Underlie ItsMultiple Physiological Functions
CCKLPBN neurons, independently of glutamate
transmission and via their projections to SF1VMH
neurons, mediate counter-regulatory responses
to glucoprivation (Garfield et al., 2014). CGRPLPBN
neurons, located in the outer-external division
of LPBN, mediate malaise-induced anorexia via
their projections to CeA[LC] (Carter et al.,
2013). Hypothetically, non-CGRP, VGlut2LPBN
neurons located in dorsolateral LPBN mediate
appetite suppression in the absence of malaise
(satiation) by recruiting a currently unidentified
downstream target. CeA[LC], lateral capsular
division of central amygdala; CCK+, cholecysto-
kinin peptide-expressing neurons of LPBN;
CGRP+, calcitonin gene-related peptide-express-
ing neurons of LPBN; LPBN, lateral parabrachial
nucleus; VGlut2+, Vesicular glutamate trans-
porter 2-expressing neurons of LPBN; SF1VMH,
SF1-positive neurons of ventromedial hypothal-
amus.
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Previewsan increase in blood glucose concentra-
tions concomitantly to stimulating sympa-
thoexcitatory drive and elevating serum
levels of the counter-regulatory hormones
glucagon and corticosterone. In sum,
CCKLPBN neurons are necessary and
sufficient for the generation of counter-
regulatory physiological responses to
glucoprivation.
An additional important observation by
Garfield et al. (2014) was that identical
experiments, when performed in Vglut2-
IRES-Cre mice, did not recapitulate the
effects obtained with CCK-IRES-Cre
mice. In other words, the dense LPBNglu-
tamatergic population does not seem be
involved in defending normoglycemia.
This is consistent with their observation
that systemic treatment with CCK-recep-
tor antagonists abrogated DREADD-
driven elevations in blood glucose
(although it remains unclear the extent
to which peripheral, e.g., vagal, signals
may have contributed to these results).
Finally, Garfield et al. (2014) studied the
candidate CCK-sensitive downstream
targets of CCKLPBN neurons. Using Cre-
dependent anterograde tract tracers, the
authors described a selective, yet dense,
projection from CCKLPBN neurons to
CCK-excited SF1 cells located in the dor-934 Cell Metabolism 20, December 2, 2014 ªsomedial aspect of the ventromedial hy-
pothalamus (SF1VMH). Although silencing
of SF1VMH neurons alone did not affect
blood glucose levels during normogly-
cemia, the same treatment attenuated
counter-regulatory responses in animals
sustaining glucoprivation.
These new findings raise on their own
right a number of intriguing questions.
First comes the issue of which intracellular
mechanisms may mediate the sensitivity
of CCKLPBN neurons to extracellular
glucose. The mechanisms controlling
glucose-excited neuronal firing are
believed to be similar to those operating
in insulin-secreting beta cells of the
pancreas, namely, an energy-consuming
cascade of events linking glucokinase
(GK) activation to the closure of ATP-sen-
sitive potassium (KATP) channels (Levin
et al., 2008). However, glucose-inhibited
neurons are suspected to function inde-
pendently of metabolic GK/KATP path-
ways. In fact, in the case of glucose-in-
hibited lateral hypothalamic orexin
neurons, increasing ATP levels via lactate
administration does not result in changes
in firing rate, implying that glucose may
act via (currently undetermined) mem-
brane glucose receptors (Burdakov et al.,
2006). Thus, one important open question
for future investigations is to determine
whether a common cellular mechanism
acts to suppress firing rate in diverse pop-
ulations of glucose-inhibited cells such as
CCKLPBN and orexin neurons. Likewise,
further studies may determine the down-
stream pathways via which SF1VMH neu-
rons activate counter-regulatory auto-
nomic drive during glucoprivation.
A second, possibly more pressing,
issue is whether—despite whole-cell
recording data demonstrating their
glucose sensing functions—CCKLPBN
neurons are controlled by peripheral glu-
cosensors in vivo. In fact, the LPBN is
located in the neuronal pathway of
ascending viscerosensory afferents (Ri-
naman and Schwartz, 2004), many of
which display glucosensing capabilities.
Specifically, portal vein infusions of
glucose, at concentrations ineffec-
tive when injected systemically, induce
increased Fos expression (a surrogate
for neuronal activation) in the LPBN of
rats (Delaere et al., 2013). This finding
strongly suggests that LPBN is sensitive
to the activation of glucosensors located
on the portal-mesenteric system. Addi-2014 Elsevier Inc.tional studies involving peripheral deaffer-
entation in combination of perturbations
of CCKLPBN activity are required for a fuller
understanding of the glucosensing me-
chanics of these neurons. Along those
lines, in a separate publication the authors
do in fact complement the pre-
sent findings by establishing that the
glucose-inhibited responses in CCKLPBN
are modulated by systemic leptin (Flak
et al., 2014). In other words, normoglyce-
mia-defending CCKLPBN neurons are
multimodal sensors, monitoring periph-
eral signals that are not limited to glucose
levels per se. How exactly intra-cellular
cascades triggered by activation of
functional leptin receptors integrate with
glucosensing mechanisms indubitably
warrants further investigation. Also
noteworthy is the authors’ finding that
CCKLPBN neurons are not involved in
appetite regulation. Consistently, cyto-
toxic lesions of LPBN are known to not
disrupt hyperphagic responses to the glu-
coprivic agent 2-deoxy-D-glucose (Calin-
gasan and Ritter, 1993). However, lesions
of PBN abrogate the ability of sweet-blind
mutant mice to form preferences for nutri-
tive glucose solutions (de Araujo, 2009).
This early demonstration of parabrachial
glucose-sensing capabilities thus sug-
gests the existence of separate neuronal
LPBN populations mediating appetite
regulation versus defense of
normoglycemia.
In this context, it is interesting to bring
about once more the negative results
associated with perturbing VGlut2LPBN
neuronal activity. It is conceivable that
VGlut2LPBN neurons, specifically those
located outside of the LPBN outer
external division (i.e., non-coincident with
CGRPLPBN neurons), mediate nutrient
sensing and satiation independently of
malaise. Note that, whereas the gluco-
sensing capabilities of CCKLPBN neurons
appear to be exclusively effectuated
by downstream SF1VMH neurons, the
malaise-related anorectic functions of
CGRPLPBN neurons depend on their effer-
ents to the lateral capsular aspect of the
central amygdalar nucleus (Carter et al.,
2013). It is therefore plausible to hypothe-
size that satiation depends on non-CGRP
VGlut2LPBN neurons located in the more
dorsolateral aspects of LPBN and that
these putative cells recruit a third
(currently unidentified) afferent region as
its downstream effector (see Figure 1).
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PreviewsFuture investigations, making use of
modern molecular tools and taking
advantage of the genetic diversity of
LPBN, must contribute to further dissect
the circuitry underlying the multiple phys-
iological roles of this pontine nucleus
whose integrity is critical for survival.REFERENCES
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Disruptions in cholesterol homeostasis contribute to cardiovascular disease (CVD). In a recent issue of Cell
Metabolism, Demetz et al. (2014) report that endogenous lipoxygenase-mediated metabolism of another
lipid, arachidonic acid, produces lipoxins that regulate reverse cholesterol transport. These results suggest
that lipoxins may represent a novel class of therapeutics for CVD.Myocardial infarction and stroke are the
primary clinical manifestations of athero-
sclerosis, a pathology associated with
accumulation of cholesterol and inflam-
matory cells in the vasculature. An
imbalance in the production, tissue de-
livery, and removal of cholesterol is a
key underlying factor in the develop-
ment of atherosclerosis because subinti-
mal accumulation of low-density lipo-
protein-associated cholesterol (LDL-C)
renders it susceptible to oxidative modi-
fication and promotes a robust immune
response (Libby et al., 2014). Immune
cells, including macrophages, are re-
cruited to sites of cholesterol deposition
in a maladaptive response that ulti-
mately leads to the formation of a
detritus lesion prone to rupture and sub-
sequent thrombosis (Libby et al., 2014).
However, macrophages also play a
role in reverse cholesterol transport
(RCT), a process in which transfer of
cholesterol to high-density lipoprotein(HDL) enables the return of excess
cholesterol to the liver for excretion in
the form of bile acids (Rosenson et al.,
2012). As such, delineation of factors
that enhance RCT has potential to lead
to the development of novel therapeu-
tics for CVD.
In a recent issue of Cell Metabolism,
Demetz et al. (2014) identify lipid media-
tors generated from omega-6 polyunsat-
urated fatty acid (PUFA), arachidonic
acid (AA), as novel regulators of RCT.
Analogous to the ‘‘good cholesterol:
bad cholesterol’’ classification of HDL
and LDL, respectively, PUFA are gener-
ally regarded as being beneficial for
CVD, whereas saturated fats have nega-
tive associations with CVD. The work by
Demetz et al. (2014) highlights a potential
mechanism underlying the beneficial ef-
fects of PUFA in this regard. Starting
from analysis of previous genome-wide
association studies (GWASs), Demetz
et al. (2014) uncover arachidonate 5-lip-oxygenase (ALOX5) SNPs that are
related to HDL-C levels and function in
humans. This suggests that AA-derived
mediators may regulate cholesterol
metabolism.
To identify such products of AA meta-
bolism, Demetz et al. (2014) first used a
pharmacologic approach with aspirin to
promote shunting of AA from cyclooxy-
genase (COX) to lipoxygenase (LOX)
pathways. In these experiments, aspirin
was administered to mice and RCT was
monitored by following the distribution
of radiolabeled [3H]-cholesterol in the
plasma, bile, and feces. This analysis
demonstrated that aspirin decreased
accumulation of [3H]-cholesterol in the
plasma, while it enhanced the appear-
ance of [3H]-sterols in the bile and feces,
suggesting increased RCT. Mechanisti-
cally, aspirin treatment enhanced bile
acid transport via the ATP-binding
cassette subfamily B member 11
(Abcb11; also known as bile salt exportDecember 2, 2014 ª2014 Elsevier Inc. 935
